Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial

BACKGROUND: STAMPEDE previously reported adding upfront docetaxel improved overall survival for prostate cancer patients starting long-term androgen deprivation therapy. We report long-term results for non-metastatic patients using, as primary outcome, metastatic progression-free survival (mPFS), an...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Nicholas D, Ingleby, Fiona C, Clarke, Noel W, Amos, Claire L, Attard, Gerhardt, Brawley, Christopher D, Chowdhury, Simon, Cross, William, Dearnaley, David P, Gilbert, Duncan C, Gillessen, Silke, Jones, Robert J, Langley, Ruth E, Macnair, Archie, Malik, Zafar I, Mason, Malcolm D, Matheson, David J, Millman, Robin, Parker, Chris C, Rush, Hannah L, Russell, J Martin, Au, Carly, Ritchie, Alastair W S, Mestre, Ricardo Pereira, Ahmed, Imtiaz, Birtle, Alison J, Brock, Susannah J, Das, Prantik, Ford, Victoria A, Gray, Emma K, Hughes, Robert J, Manetta, Caroline B, McLaren, Duncan B, Nikapota, Ashok D, O’Sullivan, Joe M, Perna, Carla, Peedell, Clive, Protheroe, Andrew S, Sundar, Santhanam, Tanguay, Jacob S, Tolan, Shaun P, Wagstaff, John, Wallace, Jan B, Wylie, James P, Zarkar, Anjali, Parmar, Mahesh K B, Sydes, Matthew R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338456/
https://www.ncbi.nlm.nih.gov/pubmed/35877084
http://dx.doi.org/10.1093/jncics/pkac043

Ejemplares similares

Ejemplares similares